ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
01 août 2023 07h00 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 8, 2023 at 8:30 a.m....
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
24 juil. 2023 07h21 HE
|
ADC Therapeutics SA
BOSTON and SHANGHAI, China and LAUSANNE, Switzerland, July 24, 2023 (GLOBE NEWSWIRE) -- Overland ADCT BioPharma, a joint venture of Overland Pharmaceuticals (CY) Inc. and ADC Therapeutics SA (NYSE:...
ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
20 juil. 2023 16h05 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, July 20, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it plans to discontinue the Phase 2 LOTIS-9 clinical trial evaluating ZYNLONTA®...
Global Cancer Antibody Drug Conjugates Market Outlook to 2029: Size, Drug Sales, Drug Dosage, Price, & Clinical Trials
16 juin 2023 06h28 HE
|
Research and Markets
Dublin, June 16, 2023 (GLOBE NEWSWIRE) -- The "Global Cancer Antibody Drug Conjugates Market Outlook 2029" report has been added to ResearchAndMarkets.com's offering.Global Cancer Antibody Drug...
ADC Therapeutics Announces Evolution of Board of Directors
15 juin 2023 07h15 HE
|
ADC Therapeutics SA
Strengthens the Board with the election of Robert W. Azelby as director Board will be comprised of nine directors; gratitude expressed for contributions of outgoing directors LAUSANNE,...
ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
09 juin 2023 07h15 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, June 09, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab...
Global Antibody Drug Conjugates Market to 2030: Rising Incidences of Cancer Worldwide Bolsters Growth
01 juin 2023 11h53 HE
|
Research and Markets
Dublin, June 01, 2023 (GLOBE NEWSWIRE) -- The "Global Antibody Drug Conjugates Market Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.The Global Antibody Drug...
ADC Therapeutics to Participate in the Jefferies Healthcare Conference
01 juin 2023 07h15 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, June 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the...
Antibody-drug Conjugates (ADC) Market Research Report 2023: Focus on Three ADC Components (Antibody, Linker, and Payload) and Clinical Trials that Display Potential
15 mai 2023 09h13 HE
|
Research and Markets
Dublin, May 15, 2023 (GLOBE NEWSWIRE) -- The "Antibody-drug Conjugates: Technology Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. This study covers several new...
Antibody-Drug Conjugates (ADCs) in Oncology Competitive Landscape Report 2023: Comprehensive Insights About 30+ Companies and 35+ Drugs
28 avr. 2023 09h23 HE
|
Research and Markets
Dublin, April 28, 2023 (GLOBE NEWSWIRE) -- The "Antibody-Drug Conjugates (ADCs) in Oncology- Competitive Landscape - 2023" report has been added to ResearchAndMarkets.com's offering.This...